Molecular and Cellular Biology, March 2000, p. 2248-2259, Vol. 20, No. 6
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Departments of Medicine1 and Cell Biology2 and Vanderbilt-Ingram Cancer Center,3 Vanderbilt University Medical Center and Department of Veterans Affairs Medical Center,4 Nashville, Tennessee 37232
Received 21 July 1999/Returned for modification 2 September 1999/Accepted 9 December 1999
| |
ABSTRACT |
|---|
|
|
|---|
Activation of the TAL1 (or SCL) gene is the most frequent gain-of-function mutation in T-cell acute lymphoblastic leukemia (T-ALL). TAL1 belongs to the basic helix-loop-helix (HLH) family of transcription factors that bind as heterodimers with the E2A and HEB/HTF4 gene products to a nucleotide sequence motif termed the E-box. Reported to act both as an activator and as a repressor of transcription, the mechanisms underlying TAL1-regulated gene expression are poorly understood. We report here that the corepressor mSin3A is associated with TAL1 in murine erythroleukemia (MEL) and human T-ALL cells. Interaction mapping showed that the basic-HLH domain of TAL1 was both necessary and sufficient for TAL1-mSin3A interaction. TAL1 was found, in addition, to interact with the histone deacetylase HDAC1 in vitro and in vivo, and a specific histone deacetylase inhibitor, trichostatin A (TSA), relieved TAL1-mediated repression of an E-box-containing promoter and a GAL4 reporter linked to a thymidine kinase minimal promoter. Further, TAL1 association with mSin3A and HDAC1 declined during dimethyl sulfoxide-induced differentiation of MEL cells in parallel with a decrease in mSin3A abundance. Finally, TSA had a synergistic effect with enforced TAL1 expression in stimulating MEL cells to differentiate, while constitutive expression of mSin3A inhibited MEL cell differentiation. These results demonstrate that a corepressor complex containing mSin3A and HDAC1 interacts with TAL1 and restricts its function in erythroid differentiation. This also has implications for this transcription factor's actions in leukemogenesis.
| |
INTRODUCTION |
|---|
|
|
|---|
Chromosomal rearrangements are frequent in hematological malignancies and typically involve genes encoding proteins, transcription factors in particular, that regulate cell growth, differentiation, or survival (8, 85). The TAL1 (or SCL) gene was initially identified as the transcriptional unit activated by a reciprocal (1;14) translocation in patients with T-cell acute lymphoblastic leukemia (T-ALL) (10, 17, 36). Activation of TAL1 transcription, generally without alteration of its coding potential, characterizes up to 60% of cases of T-ALL (9), making it the most frequent gain-of-function mutation observed in this disorder.
In addition to their expression in leukemic T cells, TAL1 transcripts
and proteins have been detected in a number of hematopoietic and
several nonhematopoietic cell types (10, 40, 41, 53, 71, 82,
101). A critical role for the gene in hematopoietic development
was shown by the finding that Tal1
/
embryos
died in midgestation with the complete absence of yolk sac blood cells
(89, 93). Tal1
/
embryonic stem
cells, in addition, failed to contribute to the hematopoietic lineages
in Tal1
/
/Tal1+/+ chimeric mice,
demonstrating that the gene is also required for blood cell formation
postnatally (81, 88). Finally, studies involving enforced
expression of TAL1 cDNAs or antisense sequences in murine
erythroleukemia (MEL) cells (2) and normal human bone marrow
cells (22, 33) indicate that TAL1 has a specific role in the differentiation of erythroid progenitors.
TAL1 belongs to the basic helix-loop-helix (bHLH) family of transcription factors, many of which regulate the differentiation of specific cellular lineages (reviewed in references 7, 24, 70, and 91). Like other tissue-restricted members of this group, TAL1 forms heterodimers with the protein products of more widely expressed HLH genes, including E2A and HEB/HTF4. These complexes were found to bind E-box sequence elements (49, 50, 103) and to stimulate transcription, particularly in association with other transcription factors or nuclear proteins (76, 77). However, transactivation of certain E-box-containing promoters was significantly lower with TAL1-E2A heterodimers than with complexes containing only E2A- or HEB/HTF4-encoded proteins (30, 51, 73), indicating that TAL1 could also act as a transcriptional repressor.
Considerable data indicate that the function of transcription factors can be modulated, if not determined, by their association with specific coregulators. A number of transcriptional coactivators, including GCN5 (13), TAFII250 (69), p300/CBP (75), PCAF (108), and SRC-1 (96), possess either intrinsic histone acetyltransferase activity or the ability to recruit proteins with such activity to chromatin. Histone acetylation is believed to destabilize nucleosomal structure, creating a permissive state for promoter activation (59). In contrast, transcriptional corepressors, including N-CoR (1, 47), SMRT (72), and mSin3 (1, 47, 72), act through recruitment of histone deacetylases (HDACs) to effect tighter nucleosomal packing and thereby restrict transcription factor accessibility. Direct physical interactions between components of coregulator complexes and the basal transcriptional machinery may also have a part in both gene repression (105) and activation (20).
By acting as integrators of signal transduction pathways, these corepressors and coactivators regulate critical steps in cellular proliferation and differentiation (reviewed in references 56, 57, and 98). p300 and CBP have been shown, in particular, to enhance the function of three erythroid transcription factors, GATA-1 (11, 12), erythroid Krüppel-like factor (112), and TAL1 (52). Further, [3H]acetate incorporation into histones increased with dimethyl sulfoxide (DMSO)-induced differentiation of wild-type but not mutant MEL cells incapable of differentiation (60), whereas the adenovirus protein E1A, an inhibitor of the histone acetyltransferases p300, CBP, and PCAF, blocked DMSO-induced MEL cell differentiation (11). In contrast, HDAC inhibitors, including trichostatin A (TSA) (109, 110) and a number of hybrid polar compounds (87), were found to induce MEL cells to differentiate.
Given the importance of both TAL1 and specific coregulators in erythroid differentiation, we investigated whether TAL1 interacts with two frequent components of nuclear corepressor complexes, mSin3A and HDAC1. We show that these proteins are associated with TAL1 in both MEL and T-ALL cell lines and that a corepressor complex containing mSin3A and HDAC1 restricts TAL1 action in erythroleukemia cell differentiation. These results have significant implications for how TAL1 function is regulated physiologically and for the mechanism by which this transcription factor acts as an oncoprotein.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture and transient transfections. MEL (F4-12B2 line) (23) and HeLa cells were cultured as described previously (52). HCD-57 cells (97) were cultured in Iscove's modified Dulbecco's medium with 20% fetal bovine serum (FBS) and 2 U of recombinant human erythropoietin per ml. Jurkat cells were cultured in RPMI 1640 medium containing 10% FBS. C3H10T1/2 cells were cultured in Dulbecco's modified Eagle medium with 10% FBS. Luciferase and chloramphenicol acetyltransferase (CAT) expression vectors were introduced into cells using Lipofectamine (Life Technologies, Gaithersburg, Md.) or SuperFect (Qiagen, Valencia, Calif.), and extracts were prepared 40 to 48 h after transfection. Luciferase and CAT assays were performed as described by De Wet et al. (27) and Nordeen et al. (74), respectively. The amount of plasmid DNA used in each transfection is detailed in the figure legends. The total mass of DNA transfected was equalized by addition of plasmid pCMV4, and each transfection was repeated three or more times.
Plasmids and constructs. Plasmid pVZmSin3A was described by Ayer et al. (3) and provided by Robert Eisenman (University of Washington, Seattle). Eukaryotic expression vector pcDNA-mSin3A was prepared by subcloning the NotI and XbaI fragment of pVZmSin3A into vector pcDNA3.1 (Invitrogen, San Diego, Calif.). The cytomegalovirus promoter-driven plasmid pcDNA-Tal1 was described previously (52). Plasmid pSV2-CAT (39) was used as an internal control for variation in transfection efficiency. A full-length mouse Tal1 cDNA was cloned into the murine stem cell virus-based bicistronic retroviral vector MSCV-IRES-GFP (murine stem cell virus-internal ribosome entry site-green fluorescent protein) (80) provided by Arthur Nienhuis (St. Jude Children's Research Hospital, Memphis, Tenn.).
Plasmids expressing glutathione S-transferase (GST)-Tal1 fusion proteins were constructed by subcloning Tal1 cDNAs generated with PCR and corresponding to amino acids 1 to 330, 1 to 144, 142 to 330, 185 to 330, 242 to 330, and 185 to 240 into vectors pGEX-3X and pGEX-5X-1. GST-HD1 was described by Yang et al. (107) and provided by Edward Seto (University of South Florida, Tampa). A full-length Tal1 cDNA was subcloned in frame with the DNA-binding domain of GAL4 (GAL41-147) in expression vector pSG424 (90). The E1bLUC-E6 reporter construct contains six copies of the preferred TAL1/E2A-binding motif 5'-AACAGATGGT-3' (50) linked to an E1b-TATA-luciferase reporter. This plasmid was provided by Richard Baer (Texas Southwestern Medical Center, Dallas) and, except for the reporter gene, is identical to E1bCAT-E6 previously reported (51). The GAL4-thymidine kinase (GAL4-TK)-luciferase reporter construct was also described previously (35). All newly constructed plasmids were characterized by restriction enzyme mapping and DNA sequencing analysis.Stable transduction.
The amphotropic retroviral packaging
cell line
NX-Ampho, provided by Garry Nolan (Stanford University,
Stanford, Calif.), was cultured in Dulbecco's modified Eagle medium
with 10% FBS. Infectious virus was produced by liposome-mediated
transfection, and virus-containing supernatants were collected 48 h after transfection and frozen in aliquots at
70°C. For retroviral
transduction, 105 exponentially growing MEL cells were
mixed with virus particles in the presence of 6 µg of Polybrene per
ml. The mixture was centrifuged for 1 h at 10,000 × g at room temperature to facilitate virus infection (4)
and returned to culture. After 5 days, GFP-expressing MEL cells were
then isolated by fluorescence-activated cell sorting and expanded in
culture. MEL cells were transfected with pcDNA-mSin3A or pcDNA3.1 by
electroporation as described previously (52), and
transductants were selected for drug resistance in 500 µg of G418 per ml.
In vitro binding assays. Translation-grade [35S]methionine was purchased from Amersham Pharmacia Biotech (Piscataway, N.J.). [35S]methionine-labeled mSin3A and TAL1 proteins were synthesized using a coupled in vitro transcription-translation system in reticulocyte lysates (TnT-coupled reticulocyte lysate system; Promega, Madison, Wis.). GST fusion proteins were expressed in the BL-21 strain of Escherichia coli and purified on glutathione-Sepharose 4B according to the manufacturer's instructions (Amersham Pharmacia Biotech). Equivalent amounts of GST fusion proteins were incubated with [35S]methionine-labeled proteins in a buffer containing 20 mM Tris HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, and 0.1 mg of bovine serum albumin per ml as previously described (52). Bound proteins were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and autoradiography.
Immunoprecipitation and immunoblot analysis. Extracts were prepared by lysing cells in radioimmunoprecipitation assay (RIPA) buffer containing 10 mM Tris Cl (pH 8.0), 140 mM NaCl, 0.025% NaN3, 0.5% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, and 2 µg of aprotinin per ml. Lysates were incubated at 4°C with protein A-Sepharose 4B (Amersham Pharmacia Biotech), precleared with preimmune immunoglobulin for 30 min to prevent nonspecific binding, and incubated with the indicated antibody for 1.5 to 2 h at 4°C. Immune complexes were recovered with protein A-Sepharose 4B and washed three times with RIPA buffer.
Quantitative immunoprecipitation analysis was carried out with 107 cells. Total cellular extracts were prepared as described above in 1.0 ml of RIPA buffer. Following preclearing with preimmune immunoglobulin, extracts were incubated with 5 µl of Tal1 antibody, and the resulting immune complexes were collected with protein A-Sepharose 4B beads. The beads were collected by centrifugation and washed, and both the mSin3A protein that coimmunoprecipitated with Tal1 and that present in an aliquot of the remaining supernatant were detected by enhanced chemiluminescence after Western transfer as described below. The fraction of total cellular mSin3A protein associated with TAL1 was determined from image analysis (NIH Image software, version 1.5) of the X-ray film. Proteins and immune complexes were prepared for immunoblot analysis by being boiled for 3 min in Laemmli loading buffer (58), fractionated by SDS-polyacrylamide gel electrophoresis, and electrotransferred to polyvinylidene difluoride membranes. Blots were blocked for 4 to 5 h in a buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl, 0.05% Tween 20, and 5% nonfat dry milk; incubated with the indicated primary antibodies overnight at 4°C; and incubated with horseradish peroxidase-conjugated secondary antibodies for 3 h at 4°C. Proteins were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech). Rabbit antibody to mouse Tal1 was described previously (53). mSin3A (K-20) and
-actin antibodies were purchased from Santa Cruz
Biotechnology (San Diego, Calif.) and Sigma Chemical Company (St.
Louis, Mo.), respectively. HDAC1 and HDAC2 antibodies were generous
gifts of Edward Seto.
HDAC assay. [3H]acetyllysine-labeled histones were prepared from MEL cells metabolically labeled with sodium [3H]acetate (ICN Pharmaceuticals, Costa Mesa, Calif.) according to the method of Carmen et al. (14). Cellular lysates intended for analysis of HDAC activity were prepared in 100 mM Tris HCl (pH 7.5)-100 mM NaCl-1% NP-40. Immune complexes were formed as described above and collected with protein A-Sepharose 4B beads, and the beads were washed three times with 100 mM Tris HCl (pH 8.0)-150 mM NaCl-1 mM EDTA-10% glycerol. HDAC activity associated with these complexes was assayed in a 200-µl reaction volume containing 100 mM Tris HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10% glycerol, and 40 µg of radiolabeled histone substrate (1.7 × 106 cpm/µg) at 37°C for 60 min. Reactions were stopped by the addition of 50 µl of 0.72 N hydrochloric acid-0.12 N acetic acid and extracted with 600 µl of ethyl acetate. The radioactivity from [3H]acetate in 500 µl of aqueous phase was determined by liquid scintillation counting. Control reactions lacking immune precipitates or containing immune precipitates coincubated with 50 nM TSA were carried out in parallel.
Northern blot analysis.
Northern blot analysis was performed
as previously described (52). Following electrophoresis,
mRNA samples were transferred to a Zeta-Probe GT blotting membrane
(Bio-Rad Laboratories, Hercules, Calif.). A 1.2-kb murine
-globin
genomic fragment provided by Maurice Bondurant (Vanderbilt University,
Nashville, Tenn.) and 0.6-kb Tal1 and 1.4-kb glyceraldehyde phosphate
dehydrogenase cDNAs were radiolabeled by random primer extension (Life
Technologies). Hybridization was carried out at 65°C overnight in
0.25 M sodium phosphate (pH 7.2)-7% SDS. Membranes were washed twice
at 65°C in 20 mM sodium phosphate (pH 7.2)-5% SDS and twice in 20 mM sodium phosphate (pH 7.2)-1% SDS before autoradiography or
PhosphorImager analysis.
Cytochemical staining. Cells were cytocentrifuged onto glass slides and stained for hemoglobin with a benzidine reagent as described previously (68). The fraction of hemoglobin-expressing cells was determined from counts of 500 consecutive cells.
| |
RESULTS |
|---|
|
|
|---|
TAL1 associates with the transcriptional corepressor mSin3A in vivo
and in vitro.
As an initial step in determining whether Tal1 and
mSin3A interact, studies were carried out using transfected HeLa cells. Extracts from cells transfected with a Tal1 expression vector or
parental vector were subjected to immunoprecipitation with a Tal1
antibody followed by immunoblot analysis with an mSin3A-specific antibody. mSin3A, which was detectable in HeLa cell extracts by direct
immunoblot analysis (Fig. 1A), was
specifically coimmunoprecipitated with Tal1 in extracts from
Tal1-transfected cells, even with high-stringency washes, but not from
cells transfected with the empty vector (Fig. 1A). To ascertain whether
Tal1 also associates with mSin3A in cells that express both proteins
physiologically, MEL cells were metabolically labeled with
[35S]methionine and cellular extracts were
immunoprecipitated with Tal1- or mSin3A-specific antibodies. A
radiolabeled protein with the mobility predicted for mSin3A was
immunoprecipitated with either antibody (data not shown), indicating
that Tal1 and mSin3A interact in this MEL cell line. To further
substantiate this interaction, coimmunoprecipitation analysis was
carried out using MEL cellular extracts. Similar to the results
obtained with Tal1-transfected cells, mSin3A was detected in immune
precipitates obtained with the Tal1 antibody but not with preimmune
immunoglobulin (Fig. 1B). These data thus demonstrate that Tal1 and
mSin3A, expressed endogenously and following transfection, can interact
in cells.
|
|
Tal1 associates with HDAC1 in vitro and in vivo.
The primary
mechanism by which the transcriptional corepressors mSin3A and mSin3B
repress transcription is by recruitment of one or more HDACs (44,
45). To determine whether TAL1-associated complexes contain
HDACs, MEL cellular extracts were subjected to immunoprecipitation with
a Tal1 antibody followed by immunoblot analysis with HDAC-specific
antibodies. As predicted, HDAC1 coimmunoprecipitated not only with
mSin3A (44) but also with Tal1 (Fig.
3A). Moreover, the amount of HDAC1
protein precipitated with the Tal1 antibody was comparable to that
precipitated with the mSin3A antibody (Fig. 3A). In contrast, HDAC2 did
not coimmunoprecipitate with Tal1, even though HDAC activity and HDAC2
protein were detected in immune precipitates obtained from these cells
with an HDAC2-specific antibody (data not shown). The reciprocal
interactions demonstrated between Tal1, mSin3A, and HDAC1 in MEL cells,
in addition to the similar kinetics with which these interactions
changed with induction of these cells to differentiate (see below),
suggest the existence of a single ternary complex containing all three
proteins.
|
Tal1-associated complexes exhibit HDAC activity.
Given that
HDAC1 protein coimmunoprecipitated with Tal1 in extracts from
erythroleukemia cells, the Tal1-associated corepressor complex
would be expected to exhibit HDAC enzymatic activity. To
investigate this issue, immune complexes from MEL cellular extracts
selected with antibodies to Tal1, mSin3A, and specific HDACs were
assayed for deacetylase activity using soluble
[3H]acetyllysine-labeled histone as substrate. As
expected (44, 45), complexes immunoprecipitated with
antibodies to mSin3A or HDAC1 showed activity toward radiolabeled
histones (Fig. 4A). Complexes
immunoprecipitated with Tal1 antibody, but not those selected with
preimmune immunoglobulin, also showed significant HDAC activity, the
specificity of which was confirmed by its complete inhibition with TSA
(Fig. 4A). These results indicate that TAL1 associates with both
immunoreactive and enzymatically active HDAC1 protein in uninduced MEL
cells.
|
Tal1-mediated transcriptional repression is relieved by TSA. We reasoned that if HDAC1 were required for TAL1-mediated repression, TAL1-mediated inhibition of transcription could be reversed with the specific HDAC inhibitor TSA. As no target genes for this transcription factor have been unequivocally established, a model promoter containing multiple copies of the preferred TAL1-E2A DNA-binding site linked to a luciferase reporter gene was employed in transient-transfection assays. Tal1 strongly inhibited luciferase activity induced by the E2A gene product E47 in transfected C3H10T1/2 cells, consistent with previous results using this promoter (51), while addition of 300 nM TSA to culture relieved this repression by more than 70% (Fig. 4B).
Both to exclude the possibility of TAL1 affecting expression by interfering with E47 binding and to determine whether TAL1 sequences could function in cis to repress transcription, a Tal1 cDNA was fused to the DNA-binding domain of the yeast transcription factor GAL4, and the resultant GAL4-TAL1 fusion was expressed in MEL cells with a luciferase reporter plasmid containing four GAL4 binding sites upstream of a minimal TK promoter. In contrast to the transcriptional activation observed with GAL41-147 fused to the coding sequences of the bHLH protein BETA-2 (data not shown), the GAL4-TAL1 fusion protein repressed reporter activity in a concentration-dependent manner (Fig. 4C), and a GAL4 fusion containing only the bHLH domain of TAL1 inhibited the activity of the TK promoter to a similar extent (data not shown). As TSA's activity in relieving repression mediated by similar GAL4-transcription factor fusions correlated with the ability of these proteins or regions of proteins to interact with HDACs (15, 26, 105), it was of interest to test the effect that this HDAC inhibitor had on the repressive function of the GAL4-TAL1 fusion protein. Similar to the E-box-containing promoter, TSA relieved GAL4-TAL1 repression of a minimal TK promoter, even stimulating reporter activity at higher concentrations, while having little or no effect on transactivation by GAL41-147 (Fig. 4D). The obvious limitations imposed by the lack of knowledge of its target genes notwithstanding, these findings suggest the involvement of an HDAC in TAL1-mediated transcriptional repression and, considered with the results of the GST pull-down and coimmunoprecipitation assays, point to a role for HDAC1 specifically.The abundance of the Tal1-associated corepressor complex decreases
with DMSO-induced MEL cell differentiation.
Coimmunoprecipitation
studies with different erythroid populations (Fig. 1C) suggested that
interaction of TAL1 and mSin3A might be affected by the extent of
cellular differentiation. To characterize the kinetics of Tal1
interaction with mSin3A and HDAC1 in differentiating MEL cells, cell
lysates were prepared at timed intervals following the addition of DMSO
to culture, the lysates were subjected to immunoprecipitation with Tal1
or mSin3A antibodies, and the presence of specific proteins in the resulting immune complexes was determined by immunoblot analysis. Tal1-
and mSin3A-containing complexes became essentially undetectable 24 h following addition of DMSO (Fig. 5A),
coincident with the time period during which these cells become
committed to differentiate (reviewed in reference
99). The abundance of mSin3A- and HDAC1-containing (Fig. 5B) and Tal1- and HDAC1-containing (Fig. 5C) complexes also decreased rapidly upon differentiation, paralleling that of the Tal1-
and mSin3A-containing complex. Taken together, these data suggest that
the concentration of a single Tal1-associated corepressor complex
containing both mSin3A and HDAC1 decreases upon DMSO-induced MEL cell
differentiation.
|
Enforced expression of Tal1 and chemical inhibition of HDAC
activity synergistically induce MEL cell differentiation.
Immunoblot analysis demonstrated that DMSO effected both an increase in
Tal1 and a decrease in mSin3A protein expression (Fig. 5D). As TAL1
overexpression had previously been shown to enhance DMSO-induced
differentiation of MEL cells (2) and a number of chemical
inhibitors of HDAC activity are inducers themselves (86,
110), we predicted that combining Tal1 overexpression with TSA
treatment could have a synergistic effect on the differentiation of
these cells. To test this possibility, MEL cells were infected with a
retroviral vector expressing a full-length Tal1 cDNA and a
GFP gene from a bicistronic transcript or the parental GFP-expressing vector alone, and polyclonal populations of transduced cells were selected by fluorescence-activated cell sorting. The cells were then
treated with 50 nM TSA for 8 days and assessed for differentiation by
histochemical staining for hemoglobin in cytospin preparations and
Northern blot analysis of
-globin mRNA expression. From two independently sorted and TSA-treated polyclonal populations, a mean of
12% of cells transduced with the parental virus stained with the
benzidine reagent (Fig. 6A). Addition of
TSA to the Tal1 transductants, in contrast, resulted in morphological
differentiation and histochemical evidence of hemoglobin expression in
a mean of 44% of cells (Fig. 6B), with few to no cells showing
evidence of differentiation in the absence of TSA (data not shown)
(2). Northern blot analysis of
-globin mRNA confirmed the
synergy between HDAC inhibition and enforced TAL1 expression (Fig. 6C).
|
Enforced expression of mSin3A inhibits DMSO-induced MEL cell
differentiation.
The dramatic decline in mSin3A protein expression
observed after addition of DMSO to MEL cells suggested that this could
in fact be required for them to differentiate. To investigate this issue, MEL cells were stably transfected with a plasmid expression vector containing a full-length mSin3A cDNA or with the
empty vector, polyclonal populations of transduced cells were selected for G418 resistance, and the extent of DMSO-induced differentiation was
determined. Immunoblot analysis showed that mSin3A-transfected cells
expressed two- to threefold more mSin3A protein than did either
nontransfected cells or cells transduced with the parental vector (data
not shown). DMSO-induced differentiation was significantly reduced in
mSin3A transductants compared to that in control cells. Specifically, a
mean of 23% of mSin3A-transfected cells stained with benzidine after 5 days in culture with DMSO (Fig. 7A)
compared to 67% of parental vector controls (Fig. 7B), and the
mSin3A-overexpressing cells also appeared much less differentiated
morphologically. Finally, in accord with cytochemical staining,
-globin mRNA levels were significantly reduced in mSin3A-transfected
cells following DMSO induction compared to those in nontransfected
populations and parental vector controls (Fig. 7C). In contrast to its
effect on differentiation, enforced mSin3A expression did not alter
Tal1 expression significantly (Fig. 7C) or affect cell
viability, and mSin3A transductants actually exhibited higher growth
rates than those of control cells (data not shown). In aggregate, these
results indicate that the decline in mSin3A protein expression is not only associated with but necessary for DMSO-induced MEL cell
differentiation.
|
| |
DISCUSSION |
|---|
|
|
|---|
We have determined that a corepressor complex interacts with the hematopoietic transcription factor TAL1 and restricts its ability to induce erythroid differentiation. We demonstrate that the corepressor mSin3A and HDAC1 are associated with TAL1 in erythroleukemia and T-ALL cell lines but not in terminally differentiated murine or human erythroid cells. The specific HDAC inhibitor TSA both relieved TAL1-mediated transcriptional repression and acted synergistically with enforced TAL1 expression in inducing MEL cells to differentiate. In contrast, mSin3A and, by inference, HDAC1 inhibited DMSO-induced MEL cell differentiation. These results provide new insights into the regulation of TAL1 transcriptional activity and define a function for mSin3A in a specific biological process.
The reduced transcriptional potency of TAL1-E2A heterodimers has been attributed both to a functional incompatibility of the two proteins' activation domains (79) and to the ability of specific regions of TAL1 to act in cis to repress transcription (48, 79). TAL1 has also been shown to inhibit MyoD-directed transcription by competing for common E protein partners and thereby preventing MyoD binding to DNA, similar to the actions of the Id proteins (38). Our finding that TAL1-directed repression could be relieved by a specific chemical inhibitor of HDACs (Fig. 4) indicates yet another mechanism by which TAL1 can inhibit transcription. The development of thymic lymphomas in E2A-deficient (6) and Id1-overexpressing (54) mice and the induction of apoptosis by overexpression or restoration, respectively, of E2A activity in TAL1-expressing Jurkat cells (78) and E2A-deficient lymphoblasts (34) provide considerable support for inhibition of E2A function being important for TAL1's actions as an oncoprotein.
Although it appears to function under a number of circumstances as a transcriptional repressor, TAL1 can also stimulate transcription (21, 76, 77). In this regard, we recently observed that the coactivator p300 augments TAL1-directed transcription and that both p300 (52) and another histone acetyltransferase, the p300/CBP-associated factor PCAF (unpublished data), coimmunoprecipitate with TAL1 in extracts from DMSO-induced MEL cells. TAL1-E2A heterodimers, in addition, interact with the products of two genes, LMO1 and LMO2, that encode transcriptional coactivators (76, 77) and are themselves activated by chromosomal translocation in T-ALL (100, 102). As the binding preferences of TAL1-E2A heterodimers (50) differ from those of complexes containing TAL1, GATA-1, Ldb-1, and LMO1 or LMO2 (103), specific sequence elements could by dictating the composition of the DNA-binding complexes influence whether TAL1 stimulates or represses transcription. For MEL cells at least, the decline in mSin3A (data herein) and Id (62, 63, 94) expression that accompanies their differentiation would also facilitate TAL1 functioning as a transcriptional activator.
In light of the differentiation-associated changes noted in mSin3A
expression, it is of considerable interest that mSin3A (Fig. 2), p300
(52), PCAF (unpublished data), and LMO1 and LMO2 (102) each apparently interact with TAL1 through the bHLH
domain. While competition for a common binding site has not yet been
established, this observation suggests that TAL1 could function as a
molecular switch, repressing transcription when associated with an
mSin3A- and HDAC1-containing complex and transactivating these same or other genes upon interaction with the coactivators p300/CBP, PCAF, and/or LMO1-LMO2. In fact, the transforming growth factor
-activated transcription factor Smad2 was shown recently to interact with a
p300/CBP-containing coactivator complex and a corepressor complex containing the homeodomain protein TGIF and HDAC1 (106). The nuclear steroid receptors are also regulated by a process in which corepressors and HDACs associate with the receptor in its unliganded state, with ligand binding promoting the dissociation of this corepressor complex and its replacement by a coactivator complex (reviewed in reference 16). Even the prototypic bHLH
transcription factor MyoD was shown recently to interact with the
nuclear corepressor N-CoR (5) in addition to the
coactivators p300/CBP (31, 83, 92, 111) and PCAF
(84). This ability of transcription factors to interact with
both coactivators and corepressors likely facilitates on-off decision
making, which may be especially useful in developmental contexts
(reviewed in reference 66).
One of our more interesting findings was that the inducibility of MEL
cells for DMSO-stimulated differentiation was affected by the
concentration and/or activity of the mSin3A- and HDAC1-containing corepressor complex. The formation of a corepressor complex for the
thyroid hormone and retinoic acid receptors was shown, similarly, to be
regulated by changes in corepressor, in that case N-CoR, expression
(95). Further, a decline in the expression of the Smad
corepressor TGIF augmented Smad2-directed transcriptional activity and
cellular responsiveness to transforming growth factor
(106), while increased expression of the coactivator PCAF
stimulated the activity of interferon regulatory factors 1 and 2 and
enhanced the responsiveness of a monocytic cell line to interferons
(67). Analogous to mSin3A in MEL cells, the expression of
N-CoR, which was found to interact with MyoD through its bHLH domain,
decreased with differentiation of C2C12 myoblasts into myotubes, and
enforced expression of this corepressor in C3H10T1/2 cells inhibited
their MyoD-induced differentiation (5). This work thus
highlights what is likely to be a general mechanism by which the
sensitivity of cells to extracellular stimuli is
regulated
differential association of transcription factors with
coregulator proteins.
While our intent in using the widely employed MEL cell model of
erythroid differentiation was to elucidate the physiologic importance
of TAL1-corepressor interaction, the finding that TAL1 interacts with
mSin3A in an erythroleukemia and, especially, a T-ALL cell line has
significant implications for its actions in leukemogenesis. A number of
other leukemia-associated oncoproteins, including AML1-ETO (37,
65, 104), TEL-AML1 (15, 35), inv(16) fusion protein
(64), BCL6/LAZ3 (25, 28, 29), PML-RAR
(42, 43, 46, 61), and PLZF-RAR
(25, 42, 43, 46, 61), also interact with corepressors and HDACs. In what may be
particularly relevant to TAL1, the ability of the normal AML1 protein
to activate transcription and to induce differentiation of a myeloid
cell line was associated with binding of p300/CBP (55),
while interaction of the chimeric AML1-ETO oncoprotein with mSin3A and
N-CoR was implicated in transcriptional repression (37, 65,
104) and inhibition of differentiation (37). Further, TSA was shown to relieve transcriptional repression mediated by a
number of these proteins (42, 43, 46, 65) and to potentiate or restore retinoid-induced differentiation in cell lines expressing the leukemia-associated retinoic acid receptor fusions (46, 61). Finally, the ability of mSin3A to inhibit differentiation and stimulate proliferation (data herein), two phenotypic hallmarks of
the neoplastic state, shows directly that these transcriptional corepressors and associated HDACs can function as oncogenic cofactors. The fact that a diverse group of transcription factors interact with
what are likely functionally equivalent corepressor complexes suggests
that common pathogenetic mechanisms underlie both myeloid and lymphoid
leukemias despite their association with different chromosomal translocations.
| |
ACKNOWLEDGMENTS |
|---|
We thank Scott Hiebert for many helpful discussions and for reviewing the manuscript; Bart Lutterbach and Rebecca Shattuck-Brandt for their suggestions on the manuscript; Yubin Shi for assistance with expression of GST fusion proteins; Robert Eisenman, Edward Seto, Garry Nolan, Arthur Nienhuis, Richard Baer, Scott Hiebert, Mark Koury, Maurice Bondurant, Roland Stein, and Sanford Krantz for providing reagents; and Victoria Richon for advice on purification of radiolabeled histones and HDAC assays.
This work was supported by National Institutes of Health grant R01 HL49118 (to S.J.B.), a Merit Review Award from the Department of Veterans Affairs (to S.J.B.), and an American Society of Hematology Fellow Scholar Award (to S.H.). Photomicroscopy was carried out in the Vanderbilt University Medical Center Imaging Resource supported by National Institutes of Health grants CA68485 and DK20593.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Hematology-Oncology, Room 547 MRB II, Vanderbilt University Medical Center, Nashville, TN 37232. Phone: (615) 936-1809. Fax: (615) 936-3853. E-mail: stephen.brandt{at}mcmail.vanderbilt.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Alland, L., R. Muhle, H. Hou, Jr., J. Potes, L. Chin, N. Schreiber-Agus, and R. A. DePinho. 1997. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49-55[CrossRef][Medline]. |
| 2. | Aplan, P. D., K. Nakahara, S. H. Orkin, and I. R. Kirsch. 1992. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J. 11:4073-4081[Medline]. |
| 3. | Ayer, D. E., Q. A. Lawrence, and R. N. Eisenman. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776[CrossRef][Medline]. |
| 4. | Bahnson, A. B., J. T. Dunigan, B. E. Baysal, T. Mohney, R. W. Atchison, M. T. Nimgaonkar, E. D. Ball, and J. A. Barranger. 1995. Centrifugal enhancement of retroviral mediated gene transfer. J. Virol. Methods 54:131-143[CrossRef][Medline]. |
| 5. |
Bailey, P.,
M. Downes,
P. Lau,
J. Harris,
S. L. Chen,
Y. Hamamori,
A. Sartorelli, and G. E. O. Muscat.
1999.
The nuclear receptor corepressor N-Cor regulates differentiation: N-Cor directly interacts with MyoD.
Mol. Endocrinol.
13:1155-1168 |
| 6. |
Bain, G.,
I. Engel,
E. C. Robanus Maandag,
H. P. te Riele,
J. R. Voland,
L. L. Sharp,
J. Chun,
B. Huey,
D. Pinkel, and C. Murre.
1997.
E2A deficiency leads to abnormalities in ![]() T-cell development and to rapid development of T-cell lymphomas.
Mol. Cell. Biol.
17:4782-4791[Abstract].
|
| 7. | Bain, G., and C. Murre. 1998. The role of E-proteins in B- and T-lymphocyte development. Semin. Immunol. 10:143-153[CrossRef][Medline]. |
| 8. | Barr, F. G. 1998. Translocations, cancer and the puzzle of specificity. Nat. Genet. 19:121-124[CrossRef][Medline]. |
| 9. |
Bash, R. O.,
S. Hall,
C. F. Timmons,
W. M. Crist,
M. Amylon,
R. G. Smith, and R. Baer.
1995.
Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group study.
Blood
86:666-676 |
| 10. |
Begley, C. G.,
P. D. Aplan,
S. M. Denning,
B. F. Haynes,
T. A. Waldmann, and I. R. Kirsch.
1989.
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif.
Proc. Natl. Acad. Sci. USA
86:10128-10132 |
| 11. |
Blobel, G. A.,
T. Nakajima,
R. Eckner,
M. Montminy, and S. H. Orkin.
1998.
CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation.
Proc. Natl. Acad. Sci. USA
95:2061-2066 |
| 12. | Boyes, J., P. Byfield, Y. Nakatani, and V. Ogryzko. 1998. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594-598[CrossRef][Medline]. |
| 13. | Brownell, J. E., J. Zhou, T. Ranalli, R. Kobayashi, D. G. Edmondson, S. Y. Roth, and C. D. Allis. 1996. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84:843-851[CrossRef][Medline]. |
| 14. |
Carmen, A. A.,
S. E. Rundlett, and M. Grunstein.
1996.
HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex.
J. Biol. Chem.
271:15837-15844 |
| 15. | Chakrabarti, S. R., and G. Nucifora. 1999. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem. Biophys. Res. Commun. 264:871-877[CrossRef][Medline]. |
| 16. | Chen, J. D., and H. Li. 1998. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Crit. Rev. Eukaryot. Gene Expr. 8:169-190[Medline]. |
| 17. | Chen, Q., J.-T. Cheng, L.-H. Tsai, N. Schneider, G. Buchanan, A. Carroll, W. Crist, B. Ozanne, M. J. Siciliano, and R. Baer. 1990. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 9:415-424[Medline]. |
| 18. |
Chen, W. Y.,
E. C. Bailey,
S. L. McCune,
J. Y. Dong, and T. M. Townes.
1997.
Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase.
Proc. Natl. Acad. Sci. USA
94:5798-5803 |
| 19. | Cheng, J. T., H. L. Hsu, L. Y. Hwang, and R. Baer. 1993. Products of the TAL1 oncogene: basic helix-loop-helix proteins phosphorylated at serine residues. Oncogene 8:677-683[Medline]. |
| 20. |
Cho, H.,
G. Orphanides,
X. Sun,
X. J. Yang,
V. Ogryzko,
E. Lees,
Y. Nakatani, and D. Reinberg.
1998.
A human RNA polymerase II complex containing factors that modify chromatin structure.
Mol. Cell. Biol.
18:5355-5363 |
| 21. | Cohen-Kaminsky, S., L. Maouche-Chretien, L. Vitelli, M. A. Vinit, I. Blanchard, M. Yamamoto, C. Peschle, and P. H. Romeo. 1998. Chromatin immunoselection defines a TAL-1 target gene. EMBO J. 17:5151-5160[CrossRef][Medline]. |
| 22. |
Condorelli, G.,
L. Vitelli,
M. Valtieri,
I. Marta,
E. Montesoro,
V. Lulli,
R. Baer, and C. Peschle.
1995.
Coordinate expression and developmental role of Id2 protein and TAL1/E2A heterodimer in erythroid progenitor differentiation.
Blood
86:164-175 |
| 23. | Coppola, J. A., and M. D. Cole. 1986. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 320:760-763[CrossRef][Medline]. |
| 24. | Dambly-Chaudiere, C., and M. Vervoort. 1998. The bHLH genes in neural development. Int. J. Dev. Biol. 42:269-273[Medline]. |
| 25. | David, G., L. Alland, S. H. Hong, C. W. Wong, R. A. DePinho, and A. Dejean. 1998. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16:2549-2556[CrossRef][Medline]. |
| 26. | De Luca, P., B. Majello, and L. Lania. 1998. Retinoblastoma protein tethered to promoter DNA represses TBP-mediated transcription. J. Cell. Biochem. 70:281-287[CrossRef][Medline]. |
| 27. |
De Wet, J. R.,
K. V. Wood,
M. DeLuca,
D. R. Helinski, and S. Subramani.
1987.
Firefly luciferase gene: structure and expression in mammalian cells.
Mol. Cell. Biol.
7:725-737 |
| 28. |
Dhordain, P.,
O. Albagli,
R. J. Lin,
S. Ansieau,
S. Quief,
A. Leutz,
J. P. Kerckaert,
R. M. Evans, and D. Leprince.
1997.
Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Proc. Natl. Acad. Sci. USA
94:10762-10767 |
| 29. |
Dhordain, P.,
R. J. Lin,
S. Quief,
D. Lantoine,
J. P. Kerckaert,
R. M. Evans, and O. Albagli.
1998.
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.
Nucleic Acids Res.
26:4645-4651 |
| 30. |
Doyle, K.,
Y. Zhang,
R. Baer, and M. Bina.
1994.
Distinguishable patterns of protein-DNA interactions involving complexes of basic helix-loop-helix proteins.
J. Biol. Chem.
269:12099-12105 |
| 31. |
Eckner, R.,
T.-P. Yao,
E. Oldread, and D. M. Livingston.
1996.
Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.
Genes Dev.
10:2478-2490 |
| 32. |
Eilers, A. L.,
A. N. Billin,
J. Liu, and D. E. Ayer.
1999.
A 13-amino acid amphipathic -helix is required for the functional interaction between the transcriptional repressor Mad1 and mSin3A.
J. Biol. Chem.
274:32750-32756 |
| 33. |
Elwood, N. J.,
H. Zogos,
D. S. Pereira,
J. E. Dick, and C. G. Begley.
1998.
Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL.
Blood
91:3756-3765 |
| 34. |
Engel, I., and C. Murre.
1999.
Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas.
Proc. Natl. Acad. Sci. USA
96:996-1001 |
| 35. |
Fenrick, R.,
J. M. Amann,
B. Lutterbach,
L. Wang,
J. J. Westendorf,
J. R. Downing, and S. W. Hiebert.
1999.
Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.
Mol. Cell. Biol.
19:6566-6574 |
| 36. |
Finger, L. R.,
J. Kagan,
G. Christopher,
J. Kurtzberg,
M. S. Hershfield,
P. C. Nowell, and C. M. Croce.
1989.
Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma.
Proc. Natl. Acad. Sci. USA
86:5039-5043 |
| 37. |
Gelmetti, V.,
J. Zhang,
M. Fanelli, and S. Minucci.
1998.
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Mol. Cell. Biol.
18:7185-7191 |
| 38. |
Goldfarb, A. N., and K. Lewandowska.
1995.
Inhibition of cellular differentiation by the SCL/tal oncoprotein: transcriptional repression by an Id-like mechanism.
Blood
85:465-471 |
| 39. |
Gorman, C. M.,
L. F. Moffat, and B. H. Howard.
1982.
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol.
2:1044-1051 |
| 40. | Green, A. R., T. Lints, J. Visvader, R. Harvey, and C. G. Begley. 1992. SCL is coexpressed with GATA-1 in hemopoietic cells but is also expressed in developing brain. Oncogene 7:653-660[Medline]. |
| 41. | Green, A. R., E. Salvaris, and C. G. Begley. 1991. Erythroid expression of the `helix-loop-helix' gene, SCL. Oncogene 6:475-479[Medline]. |
| 42. |
Grignani, F.,
S. De Matteis,
C. Nervi,
L. Tomassoni,
V. Gelmetti,
M. Cioce,
M. Fanelli,
M. Ruthardt,
F. F. Ferrara,
I. Zamir,
C. Seiser,
F. Grignani,
M. A. Lazar,
S. Minucci, and P. G. Pelicci.
1998.
Fusion proteins of the retinoic acid receptor- recruit histone deacetylase in promyelocytic leukaemia.
Nature
391:815-818[CrossRef][Medline].
|
| 43. |
Guidez, F.,
S. Ivins,
J. Zhu,
M. Soderstrom,
S. Waxman, and A. Zelent.
1998.
Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RAR underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Blood
91:2634-2642 |
| 44. | Hassig, C. A., T. C. Fleischer, A. N. Billin, S. L. Schreiber, and D. E. Ayer. 1997. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341-347[CrossRef][Medline]. |
| 45. |
Hassig, C. A.,
J. K. Tong,
T. C. Fleischer,
T. Owa,
P. G. Grable,
D. E. Ayer, and S. L. Schreiber.
1998.
A role for histone deacetylase activity in HDAC1-mediated transcriptional repression.
Proc. Natl. Acad. Sci. USA
95:3519-3524 |
| 46. |
He, L. Z.,
F. Guidez,
C. Tribioli,
D. Peruzzi,
M. Ruthardt,
A. Zelent, and P. P. Pandolfi.
1998.
Distinct interactions of PML-RAR and PLZF-RAR with co-repressors determine differential responses to RA in APL.
Nat. Genet.
18:126-135[CrossRef][Medline].
|
| 47. | Heinzel, T., R. M. Lavinsky, T. M. Mullen, M. Soderstrom, C. D. Laherty, J. Torchia, W. M. Yang, G. Brard, S. D. Ngo, J. R. Davie, E. Seto, R. N. Eisenman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48[CrossRef][Medline]. |
| 48. | Hoffmann, T. J., and M. D. Cole. 1996. The Tal1/Scl basic helix-loop-helix protein blocks myogenic differentiation and E-box dependent transactivation. Oncogene 13:617-624[Medline]. |
| 49. |
Hsu, H.-L.,
J.-T. Cheng,
Q. Chen, and R. Baer.
1991.
Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins.
Mol. Cell. Biol.
11:3037-3042 |
| 50. |
Hsu, H.-L.,
L. Huang,
J. T. Tsan,
W. Funk,
W. E. Wright,
J.-S. Hu,
R. E. Kingston, and R. Baer.
1994.
Preferred sequences for DNA recognition by the TAL1 helix-loop-helix proteins.
Mol. Cell. Biol.
14:1256-1265 |
| 51. |
Hsu, H.-L.,
I. Wadman,
J. T. Tsan, and R. Baer.
1994.
Positive and negative transcriptional control by the Tal1 helix-loop-helix protein.
Proc. Natl. Acad. Sci. USA
91:5947-5951 |
| 52. | Huang, S., Y. Qiu, R. W. Stein, and S. J. Brandt. 1999. p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. Oncogene 18:4958-4967[CrossRef][Medline]. |
| 53. |
Kallianpur, A. R.,
J. E. Jordan, and S. J. Brandt.
1994.
The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis.
Blood
83:1200-1208 |
| 54. |
Kim, D.,
X.-C. Peng, and X.-H. Sun.
1999.
Massive apoptosis in T-cell-deficient Id1 transgenic mice.
Mol. Cell. Biol.
19:8240-8253 |
| 55. | Kitabayashi, I., A. Yokoyama, K. Shimizu, and M. Ohki. 1998. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 17:2994-3004[CrossRef][Medline]. |
| 56. | Kouzarides, T. 1999. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9:40-48[CrossRef][Medline]. |
| 57. | Kuo, M. H., and C. D. Allis. 1998. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20:615-626[CrossRef][Medline]. |
| 58. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685[CrossRef][Medline]. |
| 59. | Lee, D. Y., J. J. Hayes, D. Pruss, and A. P. Wolffe. 1993. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72:73-84[CrossRef][Medline]. |
| 60. | Leiter, J. M. E., W. Helliger, and B. Puschendorf. 1984. Increase in histone acetylation and transitions in histone variants during Friend cell differentiation. Exp. Cell Res. 155:222-231[CrossRef][Medline]. |
| 61. | Lin, R. J., L. Nagy, S. Inoue, W. Shao, W. H. Miller, Jr., and R. M. Evans. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814[CrossRef][Medline]. |
| 62. |
Lister, J.,
W. C. Forrester, and M. H. Baron.
1995.
Inhibition of an erythroid differentiation switch by the helix-loop-helix protein Id1.
J. Biol. Chem.
270:17939-17946 |
| 63. | Lister, J. A., and M. H. Baron. 1998. Induction of basic helix-loop-helix protein-containing complexes during erythroid differentiation. Gene Expr. 7:25-38[Medline]. |
| 64. | Lutterbach, B., Y. Hou, K. L. Durst, and S. W. Hiebert. 1999. The inv(16) encodes an acute myeloid leukemia 1 transcription corepressor. Proc. Natl. Acad. Sci. USA 96:12822-12827 |